Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
about
Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myelomaThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaUse of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.Proteasome inhibition and its therapeutic potential in multiple myelomaProteasome inhibitors in the treatment of multiple myelomaRetrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.IMWG consensus on maintenance therapy in multiple myeloma.Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapyLong-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.Novel anti-myeloma agents and angiogenesis.Bortezomib in the front-line treatment of multiple myeloma.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.Treatment of newly diagnosed myeloma.DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesTreatment of multiple myeloma: a comprehensive review.Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.How best to use new therapies in multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Clinical impact of chromosomal aberrations in multiple myeloma.Guidelines for the diagnosis and management of multiple myeloma 2011.Bortezomib for previously untreated multiple myeloma.Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Diagnosis and therapy of multiple myeloma.Initial treatment of transplant-eligible patients in multiple myeloma.Evolving role of high dose stem cell therapy in multiple myeloma.Novel drugs for the treatment of multiple myelomaRole of bortezomib for the treatment of previously untreated multiple myeloma.Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.Changing paradigms in the treatment of multiple myeloma.Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis.Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
P2860
Q24202358-40DE05EC-F1FA-4B57-AB60-B085BB67B857Q28539605-8AC4A811-10F7-45C8-BBD2-964D4988C14CQ33376918-BFF8E7AA-0E49-4553-BFA2-0A80A7387BC8Q33632270-A5EA6F66-FFE6-439E-B14C-B2A47FB27A4DQ34063353-84EA42D5-C67C-4494-BA19-6AD97352BE3CQ34343036-38D39C5F-B34C-49B8-84D5-86B765FF40FFQ34611676-0ED2EB46-C86B-4756-9077-CEE40E481F27Q34798095-3FFF77AB-9AAE-4977-858B-22CB356FA674Q35569350-6ADEF8BE-1F61-4A82-B96B-0DC8F5C7ACC8Q35802414-796F43A2-CD97-4FA6-8F63-A2D03BCC790BQ35876966-BFD6A81D-4EFB-49A4-8B00-1E92D3E52FD1Q36141664-35DFAA86-7CB6-4345-9DE7-CC99D1B0AF70Q36251560-14DA8FB0-59C9-4AB1-9233-8FBA007AF0C9Q36525841-7393CEA2-B9ED-4483-B71C-37F385D6A1C0Q37090630-2BA32B59-A807-49D6-9CE4-01C9B7C9DB97Q37132903-4264CBC4-DFE9-4D5B-931E-1F0A987EF669Q37202761-CA2302F6-086E-4550-A392-0DC71858443EQ37280739-EF5D6710-37F2-4EC3-8BAC-9583D45C8320Q37324251-A3425BA0-F1EF-4D78-8579-810DC9B4CB73Q37350545-4C881D84-5280-4CE1-8B34-56A5EE82E310Q37454445-272703DB-330D-4471-8D07-61A5A184C8EAQ37542173-AEF6EB9B-A929-4DBD-9D9A-DCB2EB988B9BQ37546023-DFD30313-0A80-4EAE-B885-298C7F87255FQ37723000-F9A09CBA-7F4A-4082-A4F4-E219C15CF4F2Q37761370-971157DF-6669-4B8C-B36E-1821138A5D49Q37821077-437B5ED6-C559-4165-9063-2A9715604054Q37875193-6CBCD350-7A43-4FD3-9A7C-8EFAD43D1005Q37908155-6BADCC3D-F11B-4F9E-B5C8-093AE5DE8644Q38089497-3281E38F-BCF1-4363-9D24-DD4814A6DB6EQ38096055-8914B8BF-9824-44CC-9335-45F971290BF5Q38107482-0802F6F6-B20E-4C89-B824-FFE6D58F43F1Q38176061-3061BDD4-7843-4A1B-8567-D94B60BFB849Q42287525-37ACA5A9-4CA7-4255-BAC8-BF1C10D4718CQ42793018-ED851060-6A21-4951-A88F-0EE3BD2B1D84Q42807448-168E16F1-775B-4DF5-8622-60CCD7685A97Q43081275-4B6D278F-6723-4AD4-A847-37A82F66A109Q43188146-7C801327-44A8-4349-9001-534E60C168EAQ43225847-81F50EE8-9D9A-4449-BCA8-45468CC2B70BQ47583403-C496C15A-85A8-4BD2-9247-21298306D16DQ47775860-DF6219AD-26E3-4B9F-8E86-8A49A4B61CD3
P2860
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Phase II PETHEMA trial of alte ...... ns of tumor response kinetics.
@ast
Phase II PETHEMA trial of alte ...... ns of tumor response kinetics.
@en
type
label
Phase II PETHEMA trial of alte ...... ns of tumor response kinetics.
@ast
Phase II PETHEMA trial of alte ...... ns of tumor response kinetics.
@en
prefLabel
Phase II PETHEMA trial of alte ...... ns of tumor response kinetics.
@ast
Phase II PETHEMA trial of alte ...... ns of tumor response kinetics.
@en
P2093
P50
P356
P1476
Phase II PETHEMA trial of alte ...... ons of tumor response kinetics
@en
P2093
Adrián Alegre
Anna Sureda
Carlos Herrero
Helgi Van de Velde
Joan Bladé
Juan José Lahuerta
Laura Rosiñol
Maria Victoria Mateos
Pedro García-Sánchez
Xiangyang Liu
P304
P356
10.1200/JCO.2007.12.3323
P407
P577
2007-09-04T00:00:00Z